Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06406218
Other study ID # AID
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 24, 2024
Est. completion date April 30, 2026

Study information

Verified date May 2024
Source Shenyang Northern Hospital
Contact Ya-Ling Han, PhD
Phone +86 024-28897309
Email hanyaling@263.net
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Previous research has confirmed that patients undergoing percutaneous coronary intervention (PCI) can benefit from cardiac rehabilitation programs. However, there is a paucity of studies on Phase I cardiac rehabilitation commenced within three days following PCI in patients with acute myocardial infarction (AMI). Consequently, the objective of the study is to demonstrate whether Phase I cardiac rehabilitation can improve the prognosis at 12 months when compared with the control group. The primary endpoint is the Seattle Angina Questionnaire (SAQ) score at 12 months for the patients. The principal hypothesis of the study is that Phase I cardiac rehabilitation will improve the long-term prognosis for AMI patients at 12 months after PCI.


Recruitment information / eligibility

Status Recruiting
Enrollment 1100
Est. completion date April 30, 2026
Est. primary completion date April 30, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients with AMI (including STEMI and NSTEMI) who were treated in the CCU (Coronary Care Unit) for more than 12 hours after emergency PCI; 2. Patients who are expected to meet the discharge criteria without the need for repeat PCI during the current hospital stay after PCI; 3. No chest pain episodes within 8 hours, with no recurrence of myocardial infarction; remained hemodynamically stable; 4. No further increase in serum levels of cardiac biomarkers such as Creatine Kinase -MB (CK-MB) and cardiac troponins (cTn). Exclusion Criteria: 1. Patients with Killip class III or higher, or symptoms and signs of acute pulmonary edema and respiratory distress; 2. Malignant arrhythmias that cause hemodynamic instability and potentially life-threatening conditions; 3. Mechanical lesions such as ventricular wall rupture, valve or tendon rupture; 4. Patients who have not yet been weaned off ECMO, IABP, temporary pacemakers, CRRT; 5. Patients with liver or kidney dysfunction (transaminase exceeded three times the upper limit of normal; EGFR<30 ml/(minĀ·1.73m^2)) or advanced malignant tumors; 6. Patients who cannot undergo exercise rehabilitation due to orthopedic or psychiatric diseases; 7. Patients with language impairment; 8. Patients currently undergoing systematic training or participating in other clinical trials without reaching the primary endpoint collection time; 9. Researchers believe that patients are not suitable for participation in this study or have not obtained an informed consent form.

Study Design


Intervention

Behavioral:
Phase I Cardiac Rehabilitation Exercise Training
A) In the morning, take a supine position and perform straight leg raises with each leg individually, lifting to a height of 30° and holding for 3-5 seconds. Raise both arms to the side of the head to a 90° angle and hold for 5-10 seconds. Inhale deeply when exerting force and exhale slowly when lowering. Alternate between leg lifts and arm raises, performing 5 sets per session. Adjust intensity based on individual condition and may be repeated. In the afternoon, sit beside the bed for 5 minutes. B) After transitioning to secondary care according to the patient's condition, stand beside the bed for 5 minutes in the morning; in the afternoon, march in place beside the bed for 5 minutes. C) Walk beside the bed for 10 minutes per session, twice a day. D) Move around and doing activities under supervision inside the ward, 10 minutes per session, twice a day. Spend approximately one day at each level, gradually progressing the exercise to the patient's tolerance level.

Locations

Country Name City State
China General Hospital of Northern Theater Command Shenyang Liaoning

Sponsors (1)

Lead Sponsor Collaborator
Han Yaling, MD

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Seattle Angina Questionnaire (SAQ) Seattle Angina Questionnaire Score (from 0 to 500) higher scores mean a better outcome.
The assessment consists of five specific dimensions, with each dimension scored on a scale ranging from 0 to 100.
Degree of physical activity limitation.
Stable angina status.
Frequency of angina attacks.
Satisfaction with treatment.
Level of disease awareness.
6-month and 12-month
Secondary 6 minutes walking distance 6-month and 12-month
Secondary Left ventricular ejection fraction The percentage of the left ventricular stroke volume relative to the left ventricular end-diastolic volume(%). 6-month
Secondary MACCE All-cause death, myocardial infarction, stroke, revascularization again 12-month
See also
  Status Clinical Trial Phase
Recruiting NCT04451967 - Acute Myocardial Infarction Study in Northeastern China
Completed NCT05974397 - Nationwide Trends in Incidence, Healthcare Utilization, and Mortality in Hospitalized Acute Myocardial Infarction Patients in Taiwan
Not yet recruiting NCT04072081 - Drug-coated Balloon Versus Drug-eluting Stent in the Treatment of Coronary Artery Lesions in STEMI Patients in De Novo Coronary Lesions N/A
Recruiting NCT03940443 - Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
Recruiting NCT03707626 - Collateral Circulation to LAD and Wellens Sign
Completed NCT02669810 - EXCELLENT (EXpanded CELL ENdocardiac Transplantation) Phase 2
Not yet recruiting NCT04104048 - Short Term Outcome of Primary Precutaneous Coronary Intervention in Ostial Versus Non Ostial Culprit Proximal Left Anterior Descending Artery Acute Myocardial Infraction
Active, not recruiting NCT02915107 - The SORT OUT IX STEMI OCT Trial N/A
Completed NCT02896543 - The Relationship of Change of Dendritic Cells Fractalkine and P-selectin Patients With Acute Myocardial Infarction N/A
Withdrawn NCT01901471 - Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock Phase 2
Completed NCT02490969 - Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19 N/A
Completed NCT02531165 - Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention N/A
Completed NCT02312336 - A Pilot Study of Transcoronary Myocardial Cooling N/A
Recruiting NCT02071342 - Study of ABSORB Stent in Acute Myocardial Infarction N/A
Terminated NCT01972126 - MAGNetic QRS-Fragmentation in Patients With Myocardial InfarcTion and Moderately RedUceD Ejection Fraction N/A
Completed NCT02070913 - COOL-AMI EU Case Series Clinical Study
Withdrawn NCT01678339 - Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients N/A
Completed NCT01887080 - Effects of Microcurrent in a Cardiovascular Rehabilitation Home-based Program N/A
Completed NCT01216995 - Safety and Efficacy of Adipose Derived Regenerative Cells (ADRCs) Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction (AMI) Phase 2
Completed NCT01325116 - Delayed Educational Reminders in Acute Myocardial Infarction (MI) N/A